BIOAGE LABS, INC. Operating Cash Flow
BIOAGE LABS, INC. (BIOA) reported Operating Cash Flow of -$43.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.26M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$24.05M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$28.25M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$16.04M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$81.63M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$51.52M.
- BIOAGE LABS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$37.36M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$43.31M 10-Q · filed 2026-08-05 | -$71.56M derived: sum of 3 quarters · filed 2026-08-05 | -$87.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$24.05M 10-Q · filed 2026-05-08 | -$52.30M derived: sum of 2 quarters · filed 2026-05-08 | -$68.34M derived: sum of 3 quarters · filed 2026-05-08 | -$88.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$28.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$44.30M derived: sum of 2 quarters · filed 2026-03-24 | -$64.26M derived: sum of 3 quarters · filed 2026-08-05 | -$81.63M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$16.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$36.01M derived: sum of 2 quarters · filed 2026-08-05 | -$53.38M 10-Q · filed 2025-11-06 | -$58.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$19.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$37.33M 10-Q · filed 2026-08-05 | -$42.47M derived: sum of 3 quarters · filed 2026-08-05 | -$57.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$17.36M 10-Q · filed 2026-05-08 | -$22.50M derived: sum of 2 quarters · filed 2026-05-08 | -$37.43M derived: sum of 3 quarters · filed 2026-05-08 | -$53.21M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$20.07M derived: sum of 2 quarters · filed 2026-03-24 | -$35.85M derived: sum of 3 quarters · filed 2026-03-24 | -$51.52M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$14.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$30.71M derived: sum of 2 quarters · filed 2025-11-06 | -$46.38M 10-Q · filed 2025-11-06 | -$54.89M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$15.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$31.45M 10-Q · filed 2025-08-06 | -$39.96M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$15.67M 10-Q · filed 2025-05-06 | -$24.18M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$37.36M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$28.86M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |